Compare Abeona Therapeutics Inc (ABEO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs 22nd Century Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Abeona Therapeutics Inc is far larger — about 277.1× 22nd Century Group Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | XXII | |
|---|---|---|
Market Cap | $421.19M | $1.52M |
Sector | Health | Technology |
52-Week High | $7.45 | $801.00 |
52-Week Low | $4.17 | $3.72 |
Enterprise Value | $276.10M | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
